Results 31 to 40 of about 910,008 (206)

Pediatric NTRK fusion sarcomas [PDF]

, 2020
Abstract Background While ETV6-NTRK3 fusion is common in infantile fibrosarcoma, NTRK1 fusion in pediatric sarcoma is extremely rare and consequently not well known. Herein, we evaluated NTRK1 fusion pediatric sarcomas to determine their clinicopathological nature and differential diagnosis from classic ETV6-NTRK3 fusion infantile fibrosarcoma.
Jeongwan Kang, Jin Woo Park, Jae-Kyung Won, Jeong Mo Bae, Hongseok Yun, Seung-Ki Kim, Jung Yoon Choi, Hyoung Jin Kang, Joo Heon Shin, Sung-Hye Park   +9 more
openaire   +1 more source

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects [PDF]

Diagnostics, 2021
Tropomyosin receptor kinase (TK) is encoded by the neurotrophic tyrosine receptor kinase genes (NTRK) 1, 2, and 3, whose activation plays an important role in cell cycle proliferation and survival. Fusions of one of these genes can lead to constitutive activation of TRK, which can potentially be oncogenic.
Vasiliki Siozopoulou, Evelien Smits, Koen De Winne, Elly Marcq, Patrick Pauwels   +4 more
openaire   +4 more sources

MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence In Situ Hybridization Positive Colorectal Carcinomas

Frontiers in Oncology, 2021
To gain insight into the clinicopathologic profile of colorectal carcinomas harboring oncogenic NTRK fusions based on eastern populations as well as make the best testing algorithm for the screen, we use pan-Trk immunohistochemistry (IHC), fluorescence ...
Yao Fu, Zheng Li, Fuping Gao, Jun Yang, Hongyan Wu, Biao Zhang, Xiaohong Pu, Xiangshan Fan   +7 more
doaj   +1 more source

The mutual interplay between NTRK fusion genes and human papillomavirus infection in cervical cancer progression (Review). [PDF]

Mol Clin Oncol
Cervical cancer is a significant global health concern, with a substantial portion of cases attributed to human papillomavirus (HPV) infection. Recent advancements in molecular profiling have identified distinct subtypes of cervical cancer based on their
Aziz AUR, Zhang J, Zhang C, Yu X, Wang D.   +4 more
europepmc   +2 more sources

Safety of current treatment options for NTRK fusion-positive cancers. [PDF]

Expert Opin Drug Saf, 2023
Oncogenic NTRK fusions have been found in multiple cancer types affecting adults and/or children, including rare tumors with pathognomonic fusions and common cancers in which fusions are rare. The tropomyosin receptor kinase inhibitors (TRKi) larotrectinib and entrectinib are among the first agents with tissue agnostic FDA approvals for cancer ...
Yang AT, Laetsch TW.
europepmc   +3 more sources

Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers

European Thyroid Journal, 2023
Objective: The aim of the study was to identify patients with NTRK fusion-positive or RET fusion/mutation-positive thyroid cancers, who could benefit from neurotrophic tyrosine kinase receptor (NTRK) or receptor tyrosine kinase (RET) inhibitors ...
Markus Eszlinger, Paul Stewardson, John B McIntyre, Adrian Box, Moosa Khalil, Martin Hyrcza, Konstantin Koro, Dean Ruether, Jiahui Wu, Ralf Paschke   +9 more
doaj   +1 more source

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. [PDF]

Br J Cancer
While NTRK fusion-positive cancers can be exquisitely sensitive to first-generation TRK inhibitors, resistance inevitably occurs, mediated in many cases by acquired NTRK mutations.
Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, de Marchena M, Auwardt S, Sayed Ahmed S, Bremer NV, Yang SR, Feng Y, Zhou C, Kong N, Liang R, Xu H, Zhang B, Bardelli A, Toska E, Ventura A, Drilon A, Cocco E.   +21 more
europepmc   +2 more sources

Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer. [PDF]

Virchows Arch, 2023
Tropomyosin receptor kinase (TRK) inhibitors have been approved for metastatic solid tumors harboring NTRK fusions, but the detection of NTRK fusions is challenging. International guidelines recommend pan-TRK immunohistochemistry (IHC) screening followed
Schraa SJ, Stelloo E, Laclé MM, Swennenhuis JF, Brosens LAA, Fijneman RJA, Feitsma H, Koopman M, de Leng WW, Vink GR, Bol GM.   +10 more
europepmc   +2 more sources

NTRK-fusion associated sarcoma: Identification of two cases with a distinct perineurioma-like pattern

Human Pathology Reports, 2022
Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are oncogenic drivers found in a few rare tumours. However, NTRK rearrangements are being increasingly identified in a range of soft tissue neoplasms. Recognition of NTRK fusion-driven sarcomas is
Vanessa Young, Daniel Wong, Max Yan, Fiona Maclean   +3 more
doaj   +1 more source

Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report. [PDF]

Medicine (Baltimore), 2023
Rationale: Precision medicine and tumor-agnostic treatment strategies have recently been promoted for clinical use. One of the most successful treatments in patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive tumors is targeting ...
Kubota Y, Kawano M, Iwasaki T, Itonaga I, Tsumura H, Kaku N, Tanaka K.   +6 more
europepmc   +2 more sources